- FDA Approves Azstarys (serdexmethylphenidate and dexmethylphenidate) Capsules for the Once-Daily Treatment for ADHD - March 2, 2021
- KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD - March 2, 2020
Drugs Associated with KemPharm, Inc.
KemPharm, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: acetaminophen/benzhydrocodone
Drug class: narcotic analgesic combinations
Generic name: dexmethylphenidate/serdexmethylphenidate
Drug class: CNS stimulants
|2 reviews||10 / 10|
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|